Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
2024 ASCO Annual Meeting
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Charter two was found positive for the primary outcome. At the time of the report of the results, there was a statistically significant difference of five months in terms of progression-free survival in favor of the patients who received cabazitaxel plus abirateron. For patients who received cabazitaxel and abirateron, the median progression-free survival was 14.9 months versus 9.9 months for the patients who received abirateron alone. So technically, the addition of cabazitaxel prolonged the progression-free survival by a little bit more than 50%.
Even though charter two was found positive for the primary outcome, it is not a practice changing study. The main reason is because the landscape, the treatment landscape for metastatic castration-sensitive disease has changed, and there are not that many patients who are currently getting docetaxel plus androgen deprivation in the castration-sensitive setting.
Nowadays, most patients receive either a double treatment, which includes treatment with abirateron or enzalutamide or any of the other second generation androgen receptor inhibitors. In cases that the patients receive treatment with docetaxel, that is usually in the context of a triplet therapy, which means that in addition to the docetaxel, they also receive treatment with abirateron or darolutamide or enzalutamide. That is the main reason that by the time these patients develop castration-resistant disease, they have already been exposed to a second generation androgen receptor inhibitor, which of course is like abirateron.
As part of charter two, we did include two correlative studies that are in progress. The first one is the analysis of circulating tumor cells for splice variant seven, and the second one that we included in charter two was disease assessment using sodium fluoride PET imaging. This is ongoing work and hopefully we will be able to present those results in the future meeting. Also, as part of the study, we did collect plasma for patients who enrolled in the study, and we hope that we will be able to secure funding for some additional studies with those samples.
The ASCO Post Staff
Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, and Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, discuss data that appear to further support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (Abstract 7502).
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).
The ASCO Post Staff
Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.
The ASCO Post Staff
Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).
The ASCO Post Staff
Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).